September 29, 2016 / 6:16 AM / 10 months ago

BRIEF-bluebird bio and Medigene establish strategic T cell receptor alliance

1 Min Read

Sept 29 (Reuters) - Medigene AG :

* bluebird bio and Medigene establish strategic T cell receptor (TCR) alliance in cancer immunotherapy

* Medigene will be responsible for generation and delivery of TCRs using its TCR isolation and characterization platform

* Medigene will receive an upfront payment of $15 million

* Medigene will receive research and development funding for all work performed in the collaboration and is eligible for tiered royalty payments on net sales up to a double-digit percentage Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below